Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. reports news on its precision oncology business, including commercialization of KOMZIFTI™ (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Company updates also cover small-molecule drug candidates designed to target cancer signaling pathways across hematologic malignancies and solid tumors.
Recurring KURA developments include financial results, corporate updates, clinical data presentations, collaboration-related milestones, healthcare conference participation and Nasdaq inducement grants. News on darlifarnib (KO-2806) follows the company’s farnesyl transferase inhibitor program, including studies in combination with cabozantinib for clear cell renal cell carcinoma.
Kura Oncology reported Q1 2020 financials, with a net loss of $19.2 million, increasing from $13.9 million in Q1 2019. The company holds $216.9 million in cash, providing operational leverage for upcoming developments. Kura plans to emphasize its farnesyl transferase inhibitor, tipifarnib, for HRAS mutant HNSCC and the menin inhibitor, KO-539, for NPM1-mutant AML. Three abstracts on tipifarnib will be presented at ASCO 2020. Notably, development of the ERK inhibitor, KO-947, has been terminated to focus on more promising programs.
Summary not available.